Original Research
Published on 13 Nov 2025
Real-life data on pasireotide in monotherapy or combined in active Cushing’s disease
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2025.1695342
- 1,811 views
27 articles related to "Pasireotide"
Articles
Clinical Trial
Published on 09 Oct 2023
Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2023.1165681
- 8,048 views
- 24 citations
Case Report
Published on 27 Feb 2017
Medical Therapy with Pasireotide in Recurrent Cushing’s Disease: Experience of Patients Treated for At Least 1 Year at a Single Center
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2017.00035
- 4,016 views
- 8 citations
Case Report
Published on 19 Apr 2022
Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature
in Cancer Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2022.860614
- 6,268 views
- 19 citations
Case Report
Published on 18 Feb 2026
Case Report: Paradoxical responses to pasireotide in a patient with a silent corticotroph adenoma that transformed into an ACTH-secreting adenoma
in Neuro-Oncology and Neurosurgical Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1712093
- 110 views
Original Research
Published on 28 Apr 2025
Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2025.1573721
- 3,323 views
- 2 citations
Review
Published on 16 Mar 2021
Pasireotide in the Personalized Treatment of Acromegaly
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2021.648411
- 13,607 views
- 51 citations
Clinical Trial
Published on 03 Feb 2020
Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2019.00931
- 8,200 views
- 39 citations
Original Research
Published on 16 Jul 2019
Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2019.00436
- 5,449 views
- 17 citations
Original Research
Published on 21 Mar 2024
Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing’s disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2024.1250822
- 4,919 views
- 7 citations
Original Research
Published on 15 Feb 2019
Estrogens Modulate Somatostatin Receptors Expression and Synergize With the Somatostatin Analog Pasireotide in Prostate Cells
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2019.00028
- 5,670 views
- 27 citations
Review
Published on 13 Dec 2024
Pasireotide-induced hyperglycemia in Cushing’s disease and Acromegaly: A clinical perspective and algorithms proposal
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2024.1455465
- 4,154 views
- 4 citations
Mini Review
Published on 06 Feb 2020
Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2020.00028
- 6,382 views
- 8 citations
Original Research
Published on 10 Mar 2021
The Effect of 6 Months’ Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2021.633944
- 4,461 views
- 26 citations
Original Research
Published on 09 Feb 2024
Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts’ consensus statement
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2024.1348990
- 6,603 views
- 21 citations
Original Research
Published on 05 Aug 2022
Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST2 and SST5 homo- and hetero-dimer formation
in Translational and Clinical Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2022.892668
- 4,409 views
- 4 citations